FIX-HF-5CA: Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System in Subjects With Moderate-to-Severe Heart Failure With Ejection Fraction Between 25% and 45%
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 106
- 试验地点
- 17
- 主要终点
- Observed Mortality Comparison to the Predicted Probability of Mortality
研究概览
简要总结
This is a multicenter, prospective, single-arm Continued Access study of the Optimizer Smart System with CCM therapy.
详细描述
The Continued Access study is a prospective, non-randomized, multi-center study designed to allow controlled access to the Optimizer Smart System until the PMA order has been issued by the FDA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who are 18 years of age or older
- •Subjects who have a baseline ejection fraction greater than or equal to 25% and less than or equal to 45% by echocardiography.
- •Subjects who, in the opinion of the Investigator (based on the current guidelines for clinical practice), have been treated for heart failure for at least 90 days and are currently receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure.
- •Subjects who are in New York Heart Association functional Class III and IV at the time of enrollment.
- •Subjects who are willing and able to return for all follow-up visits.
排除标准
- •Subjects who have a potentially correctible cause of heart failure, such as valvular heart disease or congenital heart disease.
- •Subjects receiving any form of inotropic support within 30 days before enrollment, including subjects on continuous IV inotrope therapy.
- •Subjects hospitalized for decompensated heart failure requiring acute treatment with intravenous loop diuretics, IV inotropes or hemofiltration within 30 days before enrollment and baseline testing.
- •Subjects who have a clinically significant amount of ambient ectopy, defined as more than 8,900 PVCs per 24 hours on baseline Holter monitoring.
- •Subjects having a PR interval greater than 375ms.
- •Subjects who are scheduled for a CABG or a PTCA procedure, or who have undergone a CABG procedure within 90 days or a PTCA procedure within 30 days of enrollment.
- •Subjects who have a biventricular pacing system, an accepted indication for such a device, or a QRS width of 130ms or greater.
- •Subjects who have had a myocardial infarction within 90 days of enrollment.
- •Subjects who have mechanical tricuspid valve.
- •Subjects who have a Left Ventricular Assist Device or prior heart transplant.
- •Subjects on dialysis.
- •Subjects who are participating in another experimental protocol.
- •Subjects who are unable to provide informed consent.
研究组 & 干预措施
Optimizer Smart System
All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
干预措施: Optimizer Smart System (Device)
结局指标
主要结局
Observed Mortality Comparison to the Predicted Probability of Mortality
时间窗: 2 years 6 months
The FIX-HF-5CA Study was unofficially intended to serve as the Post-Approval Study (PAS) with the intention of collecting 3 year observed mortality data and comparing that to the predicted probability of mortality derived from two validated heart failure models \[MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) and SHFM (Seattle Heart Failure Model)\]. The objective was to show that the observed prevalence of mortality was not worse than the derived predicted probability of mortality. Upon PMA and PMA Supplement approval of the device, however, FDA and the Sponsor stopped this 5CA study and a new PAS was initiated (NCT03970343). No long-term mortality data or final analysis was collected for this study.
次要结局
未报告次要终点